Results 81 to 90 of about 79,249 (245)

Blood-brain barrier disruption and delivery of irinotecan in a rat model using a clinical transcranial MRI-guided focused ultrasound system

open access: yesScientific Reports, 2020
We investigated controlled blood-brain barrier (BBB) disruption using a low-frequency clinical transcranial MRI-guided focused ultrasound (TcMRgFUS) device and evaluated enhanced delivery of irinotecan chemotherapy to the brain and a rat glioma model ...
Nathan McDannold   +7 more
doaj   +1 more source

Stimuli‐Responsive Supramolecular Biomaterials for Cancer Theranostics

open access: yesAdvanced Science, EarlyView.
The ultimate goal of cancer theranostics is to get imaging agents and therapeutic cargo to tumor sites when and where they are required. “Smart” systems should be developed. This review discusses the characteristics of physiological stimuli, types and action modes of external stimuli, construction approaches and working principles, as well as ...
Wenting Hu   +4 more
wiley   +1 more source

Real-world outcomes of third-line immune checkpoint inhibitors versus irinotecan-based chemotherapy in patients with advanced gastric cancer: a Korean, multicenter study (KCSG ST22-06)

open access: yesBMC Cancer
Background Immune checkpoint inhibitor (ICI) or irinotecan-based chemotherapy is frequently used after failure of second-line paclitaxel plus ramucirumab treatment for patients with locally advanced unresectable or metastatic advanced gastric cancer (AGC)
Sung Hee Lim   +20 more
doaj   +1 more source

ABCB1 Genetic Variants as Predictors of Irinotecan-Induced Severe Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients

open access: yesFrontiers in Pharmacology, 2020
Irinotecan is widely used in the treatment of metastatic colorectal cancer (mCRC) despite its severe toxicities. Toxicity is often associated with the UGT1A1*28/*28 genotype.
Pau Riera   +9 more
doaj   +1 more source

A phase II study of capecitabine and oxalplatin combination chemotherapy in patients with inoperable adenocarcinoma of the gall bladder or biliary tract [PDF]

open access: yes, 2016
Background: Advanced biliary tract carcinomas are associated with a poor prognosis, and palliative chemotherapy has only modest benefit. This multi-centre phase II study was conducted to determine the efficacy of capecitabine in combination with ...
E. Soulis   +10 more
core   +1 more source

Gut Bacterium Lysinibacillus Sphaericus Exacerbates Aspirin‐induced Intestinal Injury by Production of Carboxylesterase EstB

open access: yesAdvanced Science, EarlyView.
Schematic overview illustrating the detrimental role of gut microbiota in aspirin‐induced intestinal injury. L. sphaericus and its secreted carboxylesterase EstB are identified as key drivers that catalyze aspirin hydrolysis into salicylic acid, thereby exacerbating intestinal injury. Inhibition of EstB by the dietary compound flavanomarein effectively
Zeyu Zhao   +13 more
wiley   +1 more source

P-glycoprotein-dependent pharmacokinetics of irinotecan and its active metabolite, SN-38 in rats: Effect of verapamil

open access: yesADMET and DMPK, 2015
We have recently demonstrated that the oral bioavailability of irinotecan (80 mg/kg) can be increased at least 7-fold by co-administration of the P-gp blocker verapamil (25 mg/kg, Oral).
Tripta Garg   +3 more
doaj   +1 more source

A simplified genomic profiling approach predicts outcome in metastatic colorectal cancer [PDF]

open access: yes, 2019
The response of metastatic colorectal cancer (mCRC) to the first-line conventional combination therapy is highly variable, reflecting the elevated heterogeneity of the disease.
Belardinilli, Francesca   +29 more
core   +2 more sources

Total Neoadjuvant Therapy for Rectal Cancer: Why Japan Says “Not Yet”

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
ABSTRACT Total neoadjuvant therapy (TNT) has rapidly gained global acceptance as a standard treatment for locally advanced rectal cancer (LARC). Supported by multiple phase III trials, TNT improves pathological complete response (pCR) rates, enhances systemic control, and expands opportunities for non‐operative management (NOM).
Kay Uehara   +4 more
wiley   +1 more source

Dose-Limiting Toxicities and the Maximum Tolerated Dose of Irinotecan Based on UGT1A1 Genotypes: A Systematic Review

open access: yesPharmaceutics
Background/Objectives: Irinotecan is used in monotherapy or combined with other drugs for treating different cancer streams. SN-38, the active metabolite of irinotecan, is 70% inactivated by the uridine diphosphate (UDP) glucuronosyltransferase family 1 ...
Xando Díaz-Villamarín   +9 more
doaj   +1 more source

Home - About - Disclaimer - Privacy